Indian generics giant Dr Reddy’s Laboratories announced on 13 July 2015 the launch of generic memantine hydrochloride tablets in dosages of 5 and 10 mg, following approval of the company’s abbreviated new drug application (ANDA) by the US Food and Drug Administration (FDA).
- Home
- 
                                Generics 
                                                                News- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
 Research- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
 
- 
                                Biosimilars 
                                                                News- FDA approves six denosumab biosimilars
- EMA recommends approval for four biosimilars targeting three therapies
- FDA approves first interchangeable rapid-acting insulin biosimilar, Kirsty
- ANVISA approves ranibizumab and tocilizumab biosimilars
 
- MORE EDITORIAL SECTIONS
- Search
 
                    


 
            
    
    
                         
                             
            
    
    
                                                                 
            
    
    
                                                                 
            
    
    
                                                                 
            
    
    
                                                                 
            
    
    
                                                         
            
    
    
                                                         
            
    
    
                                                        
 
            
Post your comment